Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY 94-9343) in Patients with Mesothelin Expressing Advanced or Recurrent Malignancies
Study Overview
The key purpose of the main part of the study is to assess efficacy and safety of anetumab ravtansine as monotherapy or combination therapy for mesothelin expressing advanced solid tumors.
Study Description
The key purpose of the main part of the study is to assess efficacy and safety of anetumab ravtansine as monotherapy or combination therapy for mesothelin expressing advanced solid tumors. The main purpose of the safety lead-in (dose-finding) part of the study is to determine the safety and tolerability of anetumab ravtansine in combination with cisplatin and in combination with gemcitabine, and to determine the MTD of anetumab ravtansine in combination with cisplatin for mesothelin expressing advanced cholangiocarcinoma and in combination with gemcitabine for mesothelin expressing advanced adenocarcinoma of the pancreas.
Additional Information
- IRB Number: 1706851679
- Research Study Identifier: TX8103
- Principal Investigator: Bert O'Neil, MD
Recruitment Status
OpenContact the research team to learn more about this study.
Fields marked with asterisk (*) are required
